Company Filing History:
Years Active: 2025
Title: Smita Mauze: Innovator in Anti-Cancer Therapies
Introduction
Smita Mauze is a prominent inventor based in Belmont, California. She has made significant contributions to the field of cancer treatment through her innovative research and development of combination therapies. Her work focuses on enhancing the efficacy of anti-cancer agents, particularly through the use of CTLA-4 and PD-1 blocking agents.
Latest Patents
Smita Mauze holds a patent for her groundbreaking invention titled "Anti-cancer combination therapies comprising CTLA-4 and PD-1 blocking agents." This patent discloses combination therapies that utilize a CTLA-4 blocking agent, which is an effector-silent anti-CTLA-4 antibody or its fragment, alongside a PD-1 blocking agent, such as an anti-PD-1 or anti-PD-L1 antibody or its fragment. This innovative approach aims to improve the effectiveness of cancer treatments.
Career Highlights
Smita Mauze is currently associated with Merck Sharp & Dohme Corporation, where she continues to advance her research in oncology. Her dedication to developing effective cancer therapies has positioned her as a key figure in the pharmaceutical industry. With her expertise, she contributes to the ongoing fight against cancer, striving to provide better treatment options for patients.
Collaborations
Throughout her career, Smita has collaborated with notable colleagues, including Drake LaFace and Juha Punnonen. These partnerships have fostered a collaborative environment that enhances the development of innovative cancer therapies.
Conclusion
Smita Mauze's contributions to anti-cancer therapies exemplify her commitment to improving patient outcomes through innovative research. Her patent and work at Merck Sharp & Dohme Corporation highlight her role as a leading inventor in the field of oncology.